FA - Ataxia UK

FA

New study published on goal-directed Rehabilitation vs. Standard Care in those with hereditary Cerebellar ataxia

A study led by Dr Sarah Milne at the Murdoch Children’s Research Institute, Australia, has recently been published in the journal ANNALS of Neurology. The study looked at the impact

New study published on goal-directed Rehabilitation vs. Standard Care in those with hereditary Cerebellar ataxia Read More »

Voyager Therapeutics and Neurocrine Biosciences announce selection of a lead gene therapy candidate for their FA program

On 26th February, the biotechnology company Voyager Therapeutics announced that as part of their collaboration with the biopharmaceutical company Neurocrine Biosciences, they have selected a lead development candidate in their

Voyager Therapeutics and Neurocrine Biosciences announce selection of a lead gene therapy candidate for their FA program Read More »

New study shows impacts of FA on daily life, wellbeing, and relationships in those with FA and their caregivers  

Findings from a recent study, ‘Health-related quality of life in Friedreich Ataxia: A study of impacts on patients and caregivers’, were presented at the International Society for Pharmacoeconomics and Outcomes

New study shows impacts of FA on daily life, wellbeing, and relationships in those with FA and their caregivers   Read More »

Scroll to Top